NeuroPace Reports Positive 18-Month Results from NAUTILUS Trial for Drug-Resistant Epilepsy
I'm PortAI, I can summarize articles.
NeuroPace, Inc. announced positive 18-month results from the NAUTILUS trial at the AES meeting, evaluating the RNS System for drug-resistant epilepsy. The RNS System offers personalized treatment for seizures. Details are available on NeuroPace's website. This AI-generated news brief is for informational purposes and not financial advice. Original content by NeuroPace via Business Wire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments